http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2495131-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_08b19b0d9f9ec654e71b5e8d311dde37 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-815 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 |
| filingDate | 2008-04-03^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-10-10^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8993c08785cca101beae968f1f3da94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c23fe212d247eaf6bcff5f3da3eb89b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df034109ec16c0278b4aa2ecbd62c992 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ae3f84dabc0b90e0267e084f2003e27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcdd490eef7e645f68f5220104305371 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cebfb385ca1b7969ba4e123c30e7f89a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00a7484cf231a346e943b88e1014e7b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c99e7bf281d1a12eca4b92f9e8a76c25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54d073e1bbc703e35b3883dc10fdbc64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c89223e3c1edf99d8b650f8a31124765 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9208c0be7770655d6c96e7920aba6a99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37c867227f2560c7c0b5d71d4eec3196 |
| publicationDate | 2013-10-10^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2495131-C2 |
| titleOfInvention | Method to produce recombinant insulin glargine |
| abstract | FIELD: biotechnologies. n SUBSTANCE: method includes a stage of yeast cultivation, transformed by a vector containing a DNA sequence, determined by the formula X-B-Y-A, coding the precursor of insulin glargine, where X is a sequence of leader peptide, containing at least one amino acid. B is a B1-B30 sequence of amino acids of B-chain of the insulin glargine molecule. Y is a linker peptide containing at least two amino acids. A is an A1-A21 sequence of amino acids of an A-chain of a molecule insulin glargine, a stage of extraction of an expressing precursor of insulin glargine, a stage of crystallisation of the extracted precursor of insulin glargine, a stage of completion of fermentative conversion of insulin glargine precursor crystals at pH from 8 to 10 in presence of tripsin or tripsin-like ferment and water soluble organic dissolvents at the ratio from 40% to 60% of the reaction mix with formation of insulin glargine, containing at least one related admixture. Then the stage of insulin glargine treatment by reverse phase highly efficient liquid chromatography is carried out on a chromatographic matrix, using a polar organic buffer dissolvent in a water phase, containing a buffer based on organic acid, in which the matrix is first balanced with 10% acetonitrile in 250 mM of acetic acid with further elution of insulin glargine in the specified acetonitrile. Then the matrix is again balanced with 10% acetonitrile in the buffer on the basis of organic acid in concentration from 20 mM to 200 mM at pH from 3 to 8.5 with subsequent elution of insulin glargine in the specified acetonitrile, and further repeatedly the matrix is balanced with 6% ethanol in the buffer on the basis of organic acid in concentration from 10 mM to 50 mM with subsequent elution of the specified insulin glargine in the specified ethanol. Further the treated insulin glargine is deposited by means of addition of the buffer on the basis of citric acid and zinc chloride at pH from 6 to 8. n EFFECT: invention makes it possible to produce insulin glargine with high purity and low content of glycolised admixtures. n 12 cl, 9 dwg, 8 tbl, 9 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2781307-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11655279-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2781308-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11566059-B2 |
| priorityDate | 2008-02-19^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 197 of 197.